Suppr
超能文献

Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.

作者信息

Dunn Billy, Stein Peter, Cavazzoni Patrizia

机构信息

US Food and Drug Administration, Silver Spring, Maryland.

出版信息

JAMA Intern Med. 2021 Oct 1;181(10):1276-1278. doi: 10.1001/jamainternmed.2021.4607.

DOI:10.1001/jamainternmed.2021.4607

PMID:34254984

Abstract

摘要

相似文献

Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.

JAMA Intern Med. 2021 Oct 1;181(10):1276-1278. doi: 10.1001/jamainternmed.2021.4607.

Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?

JAMA Intern Med. 2021 Oct 1;181(10):1278-1280. doi: 10.1001/jamainternmed.2021.4610.

Aducanumab (Aduhelm) for Alzheimer's disease.

Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-106.

Controversial Approval of New Drug to Treat Alzheimer's Disease.

Am J Nurs. 2021 Oct 1;121(10):22-23. doi: 10.1097/01.NAJ.0000794244.40800.99.

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.

Revisiting FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.

Can we learn lessons from the FDA's approval of aducanumab?

Nat Rev Neurol. 2021 Nov;17(11):715-722. doi: 10.1038/s41582-021-00557-x. Epub 2021 Sep 17.

Aducanumab for Alzheimer's disease: A regulatory perspective.

Pharmacol Res. 2021 Sep;171:105754. doi: 10.1016/j.phrs.2021.105754. Epub 2021 Jul 2.

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.

Brain amyloid imaging--FDA approval of florbetapir F18 injection.

N Engl J Med. 2012 Sep 6;367(10):885-7. doi: 10.1056/NEJMp1208061.

引用本文的文献

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

J Med Chem. 2025 Aug 28;68(16):17378-17411. doi: 10.1021/acs.jmedchem.5c00933. Epub 2025 Aug 8.

Aducanumab binds high molecular weight soluble Aβ oligomers and restores intracellular calcium levels.

Alzheimers Res Ther. 2025 Aug 4;17(1):180. doi: 10.1186/s13195-025-01812-9.

The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?

Alzheimers Dement. 2025 Jul;21(7):e70484. doi: 10.1002/alz.70484.

A bibliometric analysis of the current research status and hotspots regarding Aducanumab treatment for Alzheimer's disease.

Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 10. doi: 10.1007/s00210-025-04448-6.

A New Dipeptide H-MGL Partially Ameliorating Memory Impairment in an STZ-induced Alzheimer Model in Male Rats.

Basic Clin Neurosci. 2024 Sep-Oct;15(5):583-594. doi: 10.32598/bcn.2023.401.3. Epub 2024 Sep 1.

Targeting protein disorder: the next hurdle in drug discovery.

Nat Rev Drug Discov. 2025 Jun 9. doi: 10.1038/s41573-025-01220-6.

Aducanumab delivery via focused ultrasound-induced transient blood-brain barrier opening in vivo.

Sci Rep. 2025 May 22;15(1):17742. doi: 10.1038/s41598-025-02412-1.

Surrogate Marker Evaluation: A Tutorial Using R.

Stat Med. 2025 May;44(10-12):e70048. doi: 10.1002/sim.70048.

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial.

Nat Commun. 2025 May 6;16(1):4180. doi: 10.1038/s41467-025-59295-z.

Novel Phenoselenazines as Amyloid-β Aggregation Inhibitors.

ACS Med Chem Lett. 2025 Mar 17;16(4):567-574. doi: 10.1021/acsmedchemlett.4c00600. eCollection 2025 Apr 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.

JAMA Intern Med. 2021 Oct 1;181(10):1276-1278. doi: 10.1001/jamainternmed.2021.4607.

Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?

JAMA Intern Med. 2021 Oct 1;181(10):1278-1280. doi: 10.1001/jamainternmed.2021.4610.

Aducanumab (Aduhelm) for Alzheimer's disease.

Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-106.

Controversial Approval of New Drug to Treat Alzheimer's Disease.

Am J Nurs. 2021 Oct 1;121(10):22-23. doi: 10.1097/01.NAJ.0000794244.40800.99.

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.

Revisiting FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.

Can we learn lessons from the FDA's approval of aducanumab?

Nat Rev Neurol. 2021 Nov;17(11):715-722. doi: 10.1038/s41582-021-00557-x. Epub 2021 Sep 17.

Aducanumab for Alzheimer's disease: A regulatory perspective.

Pharmacol Res. 2021 Sep;171:105754. doi: 10.1016/j.phrs.2021.105754. Epub 2021 Jul 2.

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.

Brain amyloid imaging--FDA approval of florbetapir F18 injection.

N Engl J Med. 2012 Sep 6;367(10):885-7. doi: 10.1056/NEJMp1208061.

引用本文的文献

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

J Med Chem. 2025 Aug 28;68(16):17378-17411. doi: 10.1021/acs.jmedchem.5c00933. Epub 2025 Aug 8.

Aducanumab binds high molecular weight soluble Aβ oligomers and restores intracellular calcium levels.

Alzheimers Res Ther. 2025 Aug 4;17(1):180. doi: 10.1186/s13195-025-01812-9.

The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?

Alzheimers Dement. 2025 Jul;21(7):e70484. doi: 10.1002/alz.70484.

A bibliometric analysis of the current research status and hotspots regarding Aducanumab treatment for Alzheimer's disease.

Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 10. doi: 10.1007/s00210-025-04448-6.

A New Dipeptide H-MGL Partially Ameliorating Memory Impairment in an STZ-induced Alzheimer Model in Male Rats.

Basic Clin Neurosci. 2024 Sep-Oct;15(5):583-594. doi: 10.32598/bcn.2023.401.3. Epub 2024 Sep 1.

Targeting protein disorder: the next hurdle in drug discovery.

Nat Rev Drug Discov. 2025 Jun 9. doi: 10.1038/s41573-025-01220-6.

Aducanumab delivery via focused ultrasound-induced transient blood-brain barrier opening in vivo.

Sci Rep. 2025 May 22;15(1):17742. doi: 10.1038/s41598-025-02412-1.

Surrogate Marker Evaluation: A Tutorial Using R.

Stat Med. 2025 May;44(10-12):e70048. doi: 10.1002/sim.70048.

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial.

Nat Commun. 2025 May 6;16(1):4180. doi: 10.1038/s41467-025-59295-z.

Novel Phenoselenazines as Amyloid-β Aggregation Inhibitors.

ACS Med Chem Lett. 2025 Mar 17;16(4):567-574. doi: 10.1021/acsmedchemlett.4c00600. eCollection 2025 Apr 10.

Suppr超能文献

Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译